Tryptophan for Impaired AhR Signaling in Celiac Disease
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, placebo-controlled exploratory trial to
evaluate the effect of L-tryptophan supplementation on celiac-related symptoms in individuals
who have biopsy-confirmed celiac disease (CeD) and symptoms non-responsive to a gluten-free
diet (GFD). Fifty participants, aged 18 to 75 years, who self-report persistent CeD-related
symptoms despite taking a GFD for more than 1 year and who score > 40 on the Celiac Symptom
Index (CSI) will be randomized to receive L-tryptophan or placebo for 3 weeks.